keyword
MENU ▼
Read by QxMD icon Read
search

Brivaracetam

keyword
https://www.readbyqxmd.com/read/29287214/favorable-adverse-effect-profile-of-brivaracetam-vs-levetiracetam-in-a-preclinical-model
#1
Nathalie T Sanon, Jonathan Gagné, Daniele C Wolf, Soumia Aboulamer, Ciprian M Bosoi, Alexe Simard, Estelle Messiet, Sébastien Desgent, Lionel Carmant
Levetiracetam (LEV), and its newer selective analog brivaracetam (BRV), are two seizure medications that share an innovative mechanism of action targeting the Synaptic Vesicle Protein 2A (SV2A), altering neurotransmitter release and decreasing seizure frequency. Behavioral changes are the most significant adverse effects reported by patients taking LEV. We hypothesize that BRV, the more potent SV2A analog, could exert less behavioral side effects, as it requires lower doses than LEV. Using Kainic Acid (KA)-treated and control rats, we measured adverse behavioral effect profiles of LEV, BRV, or Saline, on social and nonsocial behaviors...
December 26, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29213040/-brivaracetam-in-the-treatment-of-patients-with-epilepsy
#2
V A Karlov, P N Vlasov, I A Zhidkova, M Ya Kissin, A V Lebedeva, L V Lipatova, V R Mkrtchyan, K Yu Mukhin, I G Rudakova
The newest antiepileptic drug (AED) brivaracetam (Briviac, UCB Pharma) (BRV) was approved in the Russian Federation in 2017 as an adjuvant therapy for the treatment of partial seizures with/without secondary generalization in adults and adolescents over 16 years old with epilepsy. This review contains the data of BRV preclinical studies, pharmacokinetic profile and the results of comparative study of BRV and LEV. The results of main studies of efficacy and tolerability with pooled analysis as well as data from meta-analysis are presented...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29204953/comparing-safety-and-efficacy-of-third-generation-antiepileptic-drugs-long-term-extension-and-post-marketing-treatment
#3
REVIEW
Charlotte S Kwok, Emily L Johnson, Gregory L Krauss
Four "third-generation" antiepileptic drugs (AEDs) were approved for adjunctive treatment of refractory focal onset seizures during the past 10 years. Long-term efficacy and safety of the drugs were demonstrated in large extension studies and in reports of subgroups of patients not studied in pivotal trials. Reviewing extension study and post-marketing outcome series for the four newer AEDs-lacosamide, perampanel, eslicarbazepine acetate and brivaracetam-can guide clinicians in treating and monitoring patients...
December 4, 2017: CNS Drugs
https://www.readbyqxmd.com/read/29197667/indirect-comparison-of-third-generation-antiepileptic-drugs-as-adjunctive-treatment-for-uncontrolled-focal-epilepsy
#4
Zhu Li-Na, Chen Deng, Wang Hai-Jiao, Xu Da, Tan Ge, Liu Ling
PURPOSE: Eslicarbazepine (ESL), Lacosamide (LAC), Perampanel (PER) and Brivaracetam (BRV), have recently been marketed as third-generation antiepileptic drugs (AEDs). We conducted a meta-analysis to indirectly compare overall efficacy and tolerability between third-generation AEDs in uncontrolled focal epilepsy. METHODS: We performed an online database search using Pubmed, Embase, Cochrane Online Library, and Clinicaltrial.gov for all available randomized controlled trials (RCTs) that investigated the therapeutic effects over a range of AED doses versus placebo...
November 26, 2017: Epilepsy Research
https://www.readbyqxmd.com/read/29194113/anger-assessment-in-patients-treated-with-brivaracetam
#5
Gemma Ortega, Laura Abraira, Glòria Martí, Manuel Quintana, Gonzalo Mazuela, Estevo Santamarina, Xavier Salas-Puig, Manuel Toledo
OBJECTIVES: To assess state and trait anger, adjusted by epilepsy type, seizure control, anxiety-depression status and quality of life, in patients treated with brivaracetam (BRV) from an open study. METHODS: We evaluated prospectively consecutive patients with partial onset seizures in an open-label study. Patients had 5 years or longer of epilepsy and were taking between 1 and 3 antiepileptic drugs. They were treated with BRV and compared with a control group selected from outpatients attending our epilepsy unit who met the following criteria: age ≥16 years and diagnosis of epilepsy with focal-onset seizures at least 1 year before inclusion in the study...
December 1, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29160210/exceptional-response-to-brivaracetam-in-a-patient-with-refractory-idiopathic-generalized-epilepsy-and-absence-seizures
#6
Alberto Grande-Martín, David Sopelana-Garay, José Manuel Pardal-Fernández, Rosa María Sánchez-Honrubia, Álvaro Abelardo Sánchez-Larsen
Brivaracetam is currently indicated as adjunctive therapy for patients with focal-onset seizures with or without secondary generalization. However, it has been suggested that it could provide broad-spectrum efficacy given its similarity to levetiracetam and based on the results from preclinical studies and others of patients with generalized epilepsy. We present the case of a woman with refractory idiopathic generalized epilepsy and absence seizures with dramatic response to brivaracetam. Our report supports a consideration of treatment with this new antiepileptic drug on a case-by-case basis in patients with refractory generalized epilepsy, while we await further studies on this topic...
November 21, 2017: Epileptic Disorders: International Epilepsy Journal with Videotape
https://www.readbyqxmd.com/read/29153631/human-abuse-potential-of-brivaracetam-in-healthy-recreational-central-nervous-system-depressant-users
#7
Kerri A Schoedel, Armel Stockis, Edward M Sellers
BACKGROUND: Brivaracetam is a new antiepileptic drug indicated for adjunctive treatment of focal seizures in adults at a dose of 50-200mg/day taken in two equal doses. The objective of this study was to evaluate the abuse potential of brivaracetam compared with alprazolam (positive control), placebo, and levetiracetam. METHODS: This was a randomized, double-blind, triple-dummy, crossover study in healthy male and female recreational central nervous system (CNS) depressant users aged 18-55years, who could distinguish between the subjective effects of alprazolam 2mg and placebo...
November 15, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29111505/when-adverse-effects-are-seen-as-desirable-abuse-potential-of-the-newer-generation-antiepileptic-drugs
#8
REVIEW
Kelsey L Hawkins, Barry E Gidal
There has been growing recognition of the possible abuse potential of newer generation antiepileptic drugs, and several of these agents have been categorized as controlled substances in the United States. To properly schedule a new medication, the abuse potential, or the potential for a drug to be used for its nonmedical positive subjective effects, must be determined. Performing a human abuse potential study is one step in the overall abuse potential assessment. These studies analyze the abuse potential of a new drug in a very specific population of known recreational drug users...
October 27, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29073578/long-term-retention-rates-for-antiepileptic-drugs-a-review-of-long-term-extension-studies-and-comparison-with-brivaracetam
#9
REVIEW
Manuel Toledo, Rebecca Beale, Jennifer S Evans, Sara Steeves, Sami Elmoufti, Rebecca Townsend, John Whitesides, Simon Borghs
Antiepileptic drug (AED) retention rates are frequently reported in the literature and used to inform clinical decision-making, but methodological differences in the determination of retention rates make comparisons between trials difficult. Open-label extension (OLE) studies of AEDs in patients with focal epilepsy were identified from the literature. Retention calculation methods were reviewed, and published AED retention rates qualitatively compared with corresponding data for brivaracetam (BRV), a synaptic vesicle protein 2A ligand...
October 10, 2017: Epilepsy Research
https://www.readbyqxmd.com/read/29038138/letter-re-efficacy-and-safety-of-brivaracetam-for-partial-onset-seizures-in-3-pooled-clinical-studies
#10
Pavel Klein, Selim R Benbadis, Anyzeila Diaz, Brian D Moseley, Elinor Ben-Menachem
No abstract text is available yet for this article.
October 17, 2017: Neurology
https://www.readbyqxmd.com/read/28982069/evaluation-of-brivaracetam-efficacy-as-monotherapy-in-adult-patients-with-focal-seizures
#11
Rik Schoemaker, Janet R Wade, Joseph D'Souza, Armel Stockis
Brivaracetam is a selective, high-affinity ligand for synaptic vesicle protein 2A, recently approved as adjunctive therapy in the treatment of focal (partial-onset) seizures in patients 16 years of age and older with epilepsy. The goal of the present analysis was to determine if the dose-response of brivaracetam as monotherapy would fall within the range associated with brivaracetam efficacy as adjunctive therapy. An existing brivaracetam population pharmacokinetic model consisting of first-order absorption, single compartment distribution, and first-order elimination components was extended by estimating the clearance changes due to co-administration of 12 widely prescribed AEDs...
November 2017: Epilepsy Research
https://www.readbyqxmd.com/read/28940083/efficacy-and-safety-of-antiepileptic-drugs-for-refractory-partial-onset-epilepsy-a-network-meta-analysis
#12
REVIEW
Qingting Hu, Fang Zhang, Wenhui Teng, Fangfang Hao, Jing Zhang, Mingxiao Yin, Naidong Wang
The optimal combination of antiepileptic drugs (AEDs) for the treatment of refractory partial-onset epilepsy is a perpetual point of debate. While several network meta-analyses (NMAs) have been published, conclusions remain controversial, especially since newer AEDs have been introduced. In our review, we included the newer AEDs to evaluate the comparative efficacy and safety of AEDs for the treatment of refractory partial-onset epilepsy. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (Cochrane Library 2017, Issue 1) from their inception to February 18, 2017...
September 22, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28884437/extrapolation-of-a-brivaracetam-exposure-response-model-from-adults-to-children-with-focal-seizures
#13
Rik Schoemaker, Janet R Wade, Armel Stockis
INTRODUCTION: Prediction of brivaracetam effects in children was obtained by scaling an existing adult pharmacokinetic/pharmacodynamic (PK/PD) model for brivaracetam to children, using an existing population PK model for brivaracetam in children. The scaling was supported by estimating the change from adults to children in the concentration-effect relationship parameters for levetiracetam, a compound interacting with the same target protein (synaptic vesicle protein SV2A). METHODS: The existing adult PK/PD model for brivaracetam was applied to a combined adult-pediatric dataset of levetiracetam...
September 7, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28856580/can-matching-adjusted-indirect-comparison-methods-mitigate-placebo-response-differences-among-patient-populations-in-adjunctive-trials-of-brivaracetam-and-levetiracetam
#14
Elyse Swallow, Anna Fang, James Signorovitch, Jonathan Plumb, Simon Borghs
BACKGROUND AND OBJECTIVE: Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used to indirectly compare placebo responses reported in brivaracetam and levetiracetam trials. METHODS: Patient-level data from randomised, placebo-controlled brivaracetam (recruited 2007-2014) and levetiracetam (1993-1998) trials were pooled...
October 2017: CNS Drugs
https://www.readbyqxmd.com/read/28854405/newer-antiepileptic-drugs-compared-to-levetiracetam-as-adjunctive-treatments-for-uncontrolled-focal-epilepsy-an-indirect-comparison
#15
Li-Na Zhu, Deng Chen, Da Xu, Ge Tan, Hai-Jiao Wang, Ling Liu
PURPOSE: Newer antiepileptic drugs (AEDs), such as Eslicarbazepine (ESL), Lacosamide (LAC), Perampanel (PER) and Brivaracetam (BRV), have been marketed as adjunctive treatments for partial-onset seizures. Our aim was to compare the efficacy and tolerability of newer AEDs with Levetiracetam (LEV), when used as add-on treatments for uncontrolled focal epilepsy. METHOD: We conducted an online database search on PubMed, Embase, Cochrane Online Library and Clinicaltrials...
October 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/28829199/the-preclinical-discovery-and-development-of-brivaracetam-for-the-treatment-of-focal-epilepsy
#16
REVIEW
Emilio Russo, Rita Citraro, Marco Mula
Brivaracetam (BRV) is a new AED currently licensed for the adjunctive treatment of adult patients with focal epilepsies. It is a ligand of the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Areas covered: This paper covers the preclinical and subsequent clinical development of BRV focusing on the discovery of the SV2A protein as the main target for levetiracetam (LEV) and the main similarities and differences between LEV and BRV in terms of pharmacodynamic and pharmacokinetic properties. Phase II and Phase III studies are also presented and data from post-marketing phase IV studies are discussed...
November 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/28799510/safety-profile-of-the-newest-antiepileptic-drugs-a-curated-literature-review
#17
Caterina Palleria, Giuseppe Cozza, Rajeshree Khengar, Vincenzo Libri, Giovambattista De Sarro
BACKGROUND: Despite the introduction of new antiepileptic drugs (AEDs), the quality of life and therapeutic response for patients with epilepsy remain unsatisfactory. In addition, whilst several antiepileptic drugs (AEDs) have been approved and consequently marketed in recent years, little is known about their long-term safety and tolerability. Availability of the newest AEDs, characterized by improved pharmacokinetic profiles, has positively impacted the treatment approach for patients with partial seizures in clinical practice...
August 9, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28798518/brivaracetam
#18
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Australian Prescriber
https://www.readbyqxmd.com/read/28737479/evaluation-of-brivaracetam-a-new-drug-to-treat-epilepsy
#19
Jasmina R Milovanović, Slobodan M Janković, Ana Pejčić, Miloš Milosavljević, Valentina Opančina, Vesela Radonjić, Zoran Protrka, Marina Kostić
High prevalence of therapy-resistant epilepsy demands development of anticonvulsants with new mechanisms of action. Brivaracetam is an analogue of levetiracetam which binds to the synaptic vesicle protein 2A (SV2A) and decreases release of excitatory neurotransmitters. Areas covered: Relevant published studies were searched for by predefined strategy in MEDLINE, EBSCO and SCINDEKS electronic databases. Brivaracetam is effective as adjunctive therapy for uncontrolled partial-onset seizures with or without secondary generalization in patients 16 years and older with epilepsy...
July 28, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28600961/uplc-ms-ms-assay-for-identification-and-quantification-of-brivaracetam-in-plasma-sample-application-to-pharmacokinetic-study-in-rats
#20
Muzaffar Iqbal, Essam Ezzeldin, Khalid A Al-Rashood
Brivaracetam (BVR) is a novel antiepileptic drug (AED), approved clinically for the treatment of partial onset seizures in adults and adolescents. It has some abuse potential and assigned to Schedule V category under the Controlled Substance Act by the Drug Enforcement Administration. Being an AED and drug of abuse, a sensitive and robust assay is necessary for determination of BVR in biological fluids. Herein, we report a sensitive and validated UPLC-MS/MS assay for identification and quantification of BVR in plasma samples...
August 15, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
keyword
keyword
110670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"